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Introduction: Leukemia belong to 31% of all childhood malignancies. Acute lymphoblastic leukemia (ALL) is the most frequent type of 
pediatric leukemia accounting for 80–85% of all cases. Progress in diagnostics and therapy of leukemia is dependent on international 
cooperation. The objective of the study was the analysis of non-hematological toxicity during intensive chemotherapy according to two 
consecutive intercontinental protocols. Patients and methods: A total number of 210 children diagnosed for ALL who were treated in 
single center between 2002 and 2018 were divided in two groups defined by therapeutic protocol: ALL IC-BFM 2002 (group 1) and ALL 
IC-BFM 2009 (group 2). Data were entered prospectively from 2002 into international ALL IC-BFM 2002 and ALL IC-BFM 2009 registry. 
Non-hematological toxicity was analyzed according to the criteria followed in protocols, compatible with CTCAE criteria. Results: The 
most frequent toxicities included hepatic toxicity with transaminitis and hyperbilirubinemia, infections, oral mucositis and gut toxicity 
with vomiting, and/or diarrhea. Non-hematological toxicity episodes calculated as a ratio per patient were comparably often observed 
in both the groups; however, the distribution was different. There were more grade III and less grade II toxicities. This was mainly 
related to significant increase in the rates of infections and transaminitis. However, there was a significant decrease in vomiting and 
central and peripheral neurotoxicity. Conclusions: Intensive treatment of ALL is burdened with frequent severe toxic and infectious 
complications. Further progress in therapy of pediatric ALL is dependent on sophisticated supportive therapy and very well experienced 
and knowledgeable therapeutic team.
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Introduction
Malignant diseases are the second cause of deaths in children, 
next to accidents and intoxications. Leukemia is the most frequent 
pediatric neoplastic disease responsible for approximately 26–31% 
of all childhood malignancies. Acute lymphoblastic leukemia (ALL) is 
the most frequent type of pediatric leukemia constituting 80–85% of 
all cases [1]. Progress in diagnostics and therapy for leukemia has led 
to the cure rate of 70–80% in the beginning of 21st century, compared 
to <1% in the 1960s of the 20th century [2, 3]. Due to the rarity of 
the disease, children with ALL are usually treated according to the 
international protocols [4, 5].
Intercontinental program ALL-IC-BFM 2002 was approved on February 
23, 2002,  in Hannover by working groups from 10 countries (Argentina, 
Chile, Croatia, Czech Republic, Hong-Kong, Hungary, Israel, Poland, 
Ukraine, and Uruguay) [6, 7]. Taking into account the intercontinental 
character of the project, it was the largest ever study in the entire history 
of pediatrics in 2002. Children with ALL in Poland from the year 2002 
were treated according to Intercontinental Cooperative ALL-IC-2002 
protocol up to the year 2011; and then up to 2018 according to ALL-
IC-2009 protocol. In children with ALL, treatment with intensive multiagent 
chemotherapy is complicated due to the toxicities and complications in 
approximately 70% of patients, regardless of the risk group [8].
Intensive multiagent chemotherapy used in therapy of childhood ALL 
might be complicated with gastrointestinal toxicity, hepatotoxicity, 
hypersensitivity reactions to L-asparaginase, asparaginase-associated 
pancreatitis, hyperlipidemia, osteonecrosis, hypertension, posterior 
reversible encephalopathy syndrome, seizures, loss of consciousness, 
methotrexate-associated neurotoxicity, polyneuropathy, sinusoidal 
obstruction syndrome, thrombosis, pneumonia, and other infections [9]. 
The profile of toxicities after multidrug chemotherapy in ALL is very wide 
and also includes many rare complications, such as intestinal perforation 
[10]. Hypersensivity asparaginase-associated reactions include silent 
inactivation, skin rash, and abdominal reactions such as abdominalgia 
and vomiting [11]. Pancreatitis usually is not life-threatening but might 
lead to delays in chemotherapy, thus increasing the risk of leukemic 
relapse. Osteonecrosis, hypertension, and hyperlipemia are associated 
with the use of steroids. These complications can lead to late cardio-
vascular disease, thrombolytic sequelae, or pathological fractures [12].
The objective of the study was the analysis of non-hematological 
toxicity of intensive chemotherapy in children treated for ALL between 
2002 and 2018 with two consecutive Intercontinental Cooperative 
protocols in single center study.
Patients
A total number of 210 patients aged below 18 years at diagnosis, 
with ALL, were treated in our department between October 1, 2002, 
and September 30, 2018, with the last follow-up on March 31, 2019. 
Patients were divided into two groups defined by therapeutic protocol: 
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ALL-IC-BFM 2002 (group 1) or ALL-IC-BFM 2009 (group 2). Children 
aged <1 year were treated with Interfant-06 protocol and children 
with mature B-cell ALL were excluded from the study.
Group 1 included 115 patients treated between October 1, 2002, 
and October 31, 2011, according to ALL IC-BFM 2002 protocol, with 
median follow-up of 7.0 years  (range: 0.1–14.2). Group 2 included 
95 patients treated between November 1, 2011, and September 30, 
2018, according to ALL IC-BFM 2009 protocol, with median follow-up 
of 3.0 years (range: 0.1–8.3).
Patients were treated according to ALL IC-BFM 2002 protocol 
“A Randomized Trial of the I-BFM-SG for the Management of 
Childhood Non-B Acute Lymphoblastic Leukemia, Final Version of 
Therapy Protocol from May 3, 2002 (Hannover, Germany)” (Fig. 1A) 
and protocol ALL IC-BFM 2009, “A Randomized Trial of the I-BFM-
SG for the Management of Childhood Non-B Acute Lymphoblastic 
Leukemia Final Version of Therapy Protocol from August-14-2009 
(Hannover, Germany)” (Fig. 1B).
Diagnosis of ALL was made according to the criteria presented in 
therapeutic protocols and was based on conventional diagnostics: 
bone marrow, peripheral blood, and cerebrospinal fluid smear, as 
well as flow cytometry results of lymphoblasts immunophenotyping 
and cytogenetic and molecular results. The database was created 
according to the data of the in-patient and out-patient charts.
This was a retrospective study, approved by Local Bioethical 
Committee (KB/590/2018; 25.09.2018); however, data were retrieved 
from the database prepared prospectively for the international ALL-
IC-BFM 2002 and ALL-IC-BFM 2009 registry.
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Methods
Design of the study
The study included analysis of non-hematological toxicity, which was 
analyzed according to the requirements of respective therapeutic 
protocols, strictly based on criteria NCI CTC (National Cancer Institute 
Common Toxicity Criteria), adopted by SIOP (The International 
Society of Paediatric Oncology) and modified by GPOG (German 
Society of Pediatric Oncology/Hematology) (ALL IC-BFM 2009). The 
criteria included patient status, organ toxicity, and infectious episodes 
(Tab. I). In this study, grades II–IV of the disease were analyzed, as 
they are clinically significant.
Principles of ALL-IC-2002 protocol
Patients stratification in the protocol ALL-IC-BFM 2002 was based on 
the following factors: age at diagnosis, initial number of leukocytes, 
early response at day to therapy, two genetic markers t(9;22) and 
t(4;11), and/or their molecular markers (BCR/ABL and MLL/AF4). 
Early response to therapy was determined by response to steroid 
treatment at day 8, and bone marrow response at days 15 and 
33. According to these criteria, three risk groups were defined as 
standard (SR), intermediate (IR), and high (HR) [6, 7].
Standard risk group criteria included <1,000 blasts/mm3 in peripheral 
blood on day 8 of induction therapy; age on diagnosis between 1 and 
6 years; initial white blood cell count <20,000/mm3; bone marrow M1/
Table I. Classification of non-hematological toxicity
Grade 0 1 2 3 4
General condition Normal 
activity
Mild impairment Age-related activities 
strongly limited
Bedridden, in need of 
nursing
In need of nursing, very 
sick
Infections





Fever (°C) <38 38–39 >39–40 >40°C; for <24 hours <40°C; for >24 h
Gastrointestinal toxicity
Nausea None Adequate food intake Markedly decreased food 
intake
Almost no food intake TPN necessary
Vomiting (per day) 0 1 2–5 6–10 >10;
TPN necessary
Stomatitis None Painless ulceration, 
erythema
Painful ulceration, can 
still eat
Painful ulceration, cannot 
eat




None 2–3 4–6, or night stools or light 
cramps 
7–9 or incontinence or 
strong cramps








>N – 1.5 × N >1.5 × N – 3.0 × N >3.0 × N – 10.0 × N >10.0 × N
ALT/AST activity Normal 
for age




>N – 1.5 × N >1.5 × N – 3.0 × N >3.0 × N – 6.0 × N >6.0 × N
Proteinuria (g/L) None <3.0 3.0–10.0 >10.0 Nephrotic syndrome
Hematuria None Microscopic Macroscopic w/o clots Macroscopic with clots Transfusion required
Creatinine clearance
(ml/min/1,73m2)
≥90 60–89 40–59 20–39 ≤19
Cardiac toxicity
Arrhythmia None Asymptomatic, no therapy Recurrent, persistent, no 
therapy
Therapy required Hypotension, ventricular 
arrhythmia, defibrillation
Cardiac function Normal 
for age





ECHO: LVSF ≥30% >24–30% >20–24% >15–20% ≤15%
Neurologic toxicity
Central neurotoxicity None Transient lethargy Somnolence < 50% of the 
day, moderate disorien-
tation
Somnolence ≥ 50% of 





None Paresthesias and/or de-
creased tendon reflexes






Osteonecrosis None Asymptomatic and 
detectable only by imaging 
techniques
Symptomatic with 
decreased function, but 
no limitations in everyday 
living
Symptomatic and restric-
tions in everyday living
Symptomatic, crippling
LVSF – left-ventricle shortening fraction
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M2 on day 15 of induction therapy, and bone marrow M1 on day 33 
of induction therapy. All criteria must be fulfilled.
Intermediate risk group criteria included <1,000 blasts/mm3 in 
peripheral blood on day 8 of induction therapy; age on diagnosis 
between 1 and 6 years and/or initial white blood cell count <20,000/
mm3; bone marrow M1/M2 on day 15 of induction therapy, and bone 
marrow M1 on day 33 of induction therapy; or standard risk group 
criteria but bone marrow M3 on day 15 of induction therapy, and bone 
marrow M1 on day 33 of induction therapy.
High risk group criteria included intermediate risk group and M3 
on day 15 (but not SR and M3 on day 15); ≥1,000 blasts/mm3 in 
peripheral blood on day 8 of induction therapy; bone marrow M2/
M3 on day 33 of induction therapy; translocation t(9;22) [BCR/ABL] 
or t(4;11) [MLL/AF4]. At least one of these criteria must be fulfilled.
Principles of ALL-IC-2009 protocol
Principles of ALL IC-BFM 2009 protocols were similar to the previous 
one, with stratification into three risk groups. Presence of minimal 
residual disease (MRD) was added as a new potent stratifying factor. 
MRD was determined by flow cytometry (FC) immunophenotype 
analysis on day 15 of induction therapy. Patients stratification in 
the protocol ALL IC-BFM 2009 was based on the following factors: 
age at diagnosis, initial number of leukocytes, early response at 
day to therapy, presence of MRD, two genetic markers t(9;22) and 
t(4;11), and/or their molecular markers (BCR/ABL and MLL/AF4). 
Early response to therapy was determined by response to steroid 
treatment at day 8, and bone marrow response at day 15 and 33. 
According to these criteria, three risk groups were defined: standard 
(SR), intermediate (IR), and high (HR).
Standard risk group criteria included <1,000 blasts/mm3 in peripheral 
blood on day 8 of induction therapy; age on diagnosis between 1 
and 6 years; initial white blood cell count <20,000/mm3; MRD <0,1% 
or bone marrow M1/M2 on day 15 of induction therapy, and bone 
marrow M1 on day 33 of induction therapy. All criteria must be fulfilled.
High risk group criteria included IR and FC MRD > 10% or M3 on day 
15; SR and FC MRD >10%; ≥1,000 blasts/mm3 in peripheral blood 
on day 8 of induction therapy; bone marrow M2/M3 on day 33 of 
induction therapy; translocation t(9;22) [BCR/ABL] or t(4;11) [MLL/
AF4], and hypodiploidy ≤44 chromosomes. At least one criterion 
must be fulfilled. Intermediate risk group included all other patients 
(non-SR and non-HR).
The therapeutic modifications in the protocol, in comparison to the 
previous one, included increase of the methotrexate dose from 2 g/m2 
to 5 g/m2 in IR group of B-cell precursor ALL (BCP-ALL), and in T-ALL 
SR and IR group. In HR group, early intensification Augmented IB 
protocol was used (with additional 4 doses of vincristine and 12 doses 
of L-asparaginase). Prophylactic CNS radiotherapy of 12 Gy was 
designed only for IR patients with T-ALL and initial WBC > 100,000/ml, 
and HR patients not qualified for allo-HSCT, with the exception of 
BCP-ALL only due to PPR (prednisolone poor response).
Statistical analysis
Categorical variables were compared to the chi-square test, and 
non-categorical variables were compared to the Mann–Whitney 
U test. All reported p-values are two-sided; p < 0.05 was considered 
as statistically significant.
Results
Children in group 2 were younger, more often had hyperdiploidy 
and more often had hypodiploidy, more often had poor prednisolone 
response by day 8 of induction therapy, and there was a higher rate 
of High Risk Group patients in group 2 (Tab. II).
In group 1, overall 949 toxic episodes were noted, including 588 of 
grade II (average 5.11 episodes per patient), 271 grade III (2.36/
patient), 90 grade IV (0.78/patient) (Tab. III). Infectious complications 
were most frequent with the total of 240, including 136 grade II, 
90 grade III, and 14 grade IV. Transaminitis was the second most 
frequent complication, occurring as 216 episodes: 97 grade II, 105 
grade III, and 14 grade IV. Other toxicities included vomiting in 96 
cases, mucositis in 75 cases, worsening of overall condition in 72 
cases, diarrhea in 43 cases, elevated bilirubin serum concentration 
in 43 cases, and peripheral neuropathies in 30 cases. Rare 
complications included neurotoxicity and cardiotoxicity.
In group 2, a total number of 724 toxic episodes were observed, 
including 399 grade II (4.2 episodes per patient), 268 grade III 
(2.82/patient), and 57 grade IV (0.6/patient). Compared to previous 
protocol, transaminitis was the most frequent complication, occurring 
as 259 episodes (106 grade II, 139 grade III, and 14 grade IV), and 
followed by infectious complications in 271 episodes (158 grade II, 
108 grade III, and 5 grade IV). Other complications included mucositis 
in 78 cases and elevated bilirubin serum concentration in 40 cases. 
Cardiotoxicity and neurotoxicity occurred rarely.
In the group 2, the rate of episodes of toxicities per 1 patient was 
comparable to group 2; however, the distribution was different: there 
were more grade III and less grade II toxicities. This was mainly 
related to significant increase in rates of infections and transaminitis. 
However, there was significant decrease in vomiting and neurotoxicity, 
both central and peripheral (Tab. III).
Discussion
ALL is the most frequent pediatric malignancy. Results of treatment 
of ALL is regarded as an indicator of level of oncological care and 
management at local, national, and international level. Due to the 
relative rarity of pediatric malignancies, most of them is treated in 
international cooperation. Progress in management of ALL is based 
on the improvement of multiagent chemotherapy protocols. From the 
1970s of the 20th century, children with ALL in Poland are treated with 
the use of American or German protocols in all pediatric oncological 
centers [2, 3]. In 2002, Polish Pediatric Leukemia and Lymphoma 
Study Group joined InterContinental ALL-IC-2002 group [7]. From 
then, for 16 years up to 2018, Polish children with ALL were treated 
according to ALL-IC-2002 and ALL-IC-2009 protocols.
The concept of new protocols is based on more precise risk group 
stratifications of patients and risk group–adapted therapy, which should 
lead to higher efficacy and lower toxicity of chemotherapy. This study 
was aimed at analysis and comparison of non-hematological toxicity 
of two recent pediatric ALL protocols in single center study. All patients 
were analyzed in two groups as defined by therapeutic protocol.
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Table II. Characteristics of patients
Characteristics Group 1 Group 2 p-value


















Initial while blood cell count >20,000/ml 44 (38.3%) 29 (30.5%) 0.31

























Mediastinal involvement 10 (8.7%) 2 (2.1%) 0.08



























Hyperdiploidy 12 (10.4%) 23 (24.2%) 0.01
Hypodiploidy 0 (0%) 5 (5.3%) 0.04
Rearrangement BCR-ABL 5 (4.3%) 0 (0%) 0.04
Rearrangement MLL 0 (0%) 1 (1.5%) 0.99
Rearrangement TEL-AML1 24 (20.9%) 20 (21.1%) 0.99








Number of patients with ABC > 1,000 at day 8 4 (3.5%) 14 (14.7%) 0.01
Response to steroid therapy at day 8
- Prednisolone good responder (PGR)






Bone marrow response at day 15
- M1 (number of BM blasts <5 %)









MRD (flow cytometry) – day 15 of therapy
- <0.1%































CNS radiotherapy 17 (14.8%) 7 (7.4%) 0.14
Hematopoietic cell transplantation (in CR1) 14 (12.1%) 12 (12.6%) 0.99
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Table III. Number of episodes of non-hematological toxicity: overall and per 1 patient
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In this study, we have shown that in both groups the most frequent 
toxicities included oral and gut mucositis, vomiting, diarrhea, 
and hepatic toxicity with transaminitis and hyperbilirubinemia. 
Non-hematological toxicity episodes estimated per patient were 
comparably often observed in both groups; however, their distribution 
differed between the groups. Compared to group 1, patients in group 
2 had lower rate of vomiting and neurotoxicity. The decrease in 
vomiting reflects better level of supportive therapy performed in the 
department related to prophylactic use of antiemetic drugs. Such 
improvement in prevention of acute chemotherapy-induced nausea 
and vomiting in pediatric cancer patients is currently observed in most 
of the centers and reflects significant progress in the management of 
this complication worldwide [13, 14].
Neurotoxicity during treatment of ALL is most often presented as 
seizures, which might occur in up to 10% of children during intensive 
chemotherapy and might be caused by drug toxicity, electrolyte, 
or metabolic disturbances as well as infectious complications [9]. 
Posterior reversible encephalopathy syndrome (PRES) is another 
example of central neurotoxicity and is manifested as impaired vision, 
headaches, and seizures. It is usually caused by impaired brain 
circulation [15]. Most often peripheral neurotoxicity is the motor and 
sensory neuropathy caused by vincristine, which is always reversible 
[9]. In our department a significant decrease of neurotoxicity was 
achieved by multifactorial prophylactic strategies such as prolonged 
infusion of vincristine, if necessary; avoiding drug interaction with 
azoles; prophylaxis with anticonvulsants, if necessary; or measuring 
antibiotic trough concentration (e.g., vancomycin). These actions 
were in line with recent guidelines [16, 17].
The rate of liver toxicity including transaminitis was higher in group 2. 
This probably reflects the use of higher doses of chemotherapy in 
the second protocol. Hepatic toxicity is one of the most frequent 
complications during chemotherapy and expressed by elevated 
aminotransferases and bilirubin. Chronic hepatopathy might also 
occur during maintenance treatment with oral methotrexate and 
mercaptopurine [18]. There are no recommendations as how to 
prevent or alleviate chemotherapy-induced hepatotoxicity in children.
Infectious complications also belong to frequent complications of 
antileukemic therapy [19]. In our analysis, both absolute number 
and their rate per 1 patient has increased over the years. It should 
be noted that between 2014 and 2015, antifungal prophylaxis with 
azoles was introduced in Poland; however, due to their interaction 
with vincristine it does not decrease the rate of fungal infections in 
children with ALL [20]. Antimicrobial prophylaxis in pediatric ALL is 
not recommended [21, 22], and children are more susceptible to 
infectious complications than adults [23].
ALL currently belongs to pediatric malignancies with superior 
outcome, reaching long-term survival in over 80% of the patients [7]. 
Nevertheless, the positive effect of therapy can be compromised by 
relapses and toxic complications [8, 9].
This study has some limitations. Although we analyzed toxicity during 
intensive chemotherapy and all patients completed this stage of 
treatment, the follow-up period was significantly shorter in group 2. 
Another issue was the learning process of the team that is responsible 
for care of patients. In spite of the fact that the protocol ALL-IC-2002 
was developed on the basis on the BFM-ALL-95, which was used 
previously in the Department, still it was the new experience. In the 
next protocol, ALL-IC-2009, the experience of the therapeutic team 
in prevention of complications was much higher. This could impact 
lower rate of gut and neurological toxicities.
Patients treated for ALL after 2011 have currently 91% probability 
of overall survival [2]. The main cause of treatment failure is 
relapse; however, toxicity of chemotherapy is a severe issue 
[9, 11]. We showed that intensive treatment of ALL is burdened with 
frequent severe toxic and infectious complications. In conclusion, 
further progress in therapy of pediatric ALL will be dependent 
on sophisticated supportive therapy, very well experienced and 
knowledgeable therapeutic team.
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